Summary of adverse prognostic factors and survival outcomes of non-DLBCL monomorphic PTLD and HL-type PTLD as reported in the largest retrospective studies to date
| PTLD subtype . | Key adverse prognostic factors . | OS data . |
|---|---|---|
| BL-PTLD | Bone marrow involvement; failure to achieve CR with frontline treatment | Median OS reported as 7.1 years in one study and 139 months in another9,18 |
| T/NK-cell PTLD | EBV-negative status; PTCL-NOS and HSTCL subtypes | Median OS ∼6 months, varying by subtype12,16 |
| Plasmacytic PTLD | In plasmacytoma and plasma cell myeloma PTLD, cytogenetic abnormalities confer similar prognostic impact as in non-PTLD settings In plasmablastic lymphoma, MYC rearrangements and EBV negativity were associated with poor prognosis in one study, but not in another | Plasmacytoma-like PTLD and PCM-PTLD have survival outcomes comparable with those in the nontransplant setting14 OS in plasmablastic lymphoma ranged from 0 to 15.9 years in 1 study13 |
| PCNS-PTLD | Lack of response to high-dose MTX; older age; elevated LDH; high Ki-67 index | Median OS was 17 months in one study and 122 months in another10,11 |
| HL-PTLD | Older age; elevated creatinine; receipt of nonstandard HL therapies | 5-year OS was 57% in the largest retrospective study22 |
| PTLD subtype . | Key adverse prognostic factors . | OS data . |
|---|---|---|
| BL-PTLD | Bone marrow involvement; failure to achieve CR with frontline treatment | Median OS reported as 7.1 years in one study and 139 months in another9,18 |
| T/NK-cell PTLD | EBV-negative status; PTCL-NOS and HSTCL subtypes | Median OS ∼6 months, varying by subtype12,16 |
| Plasmacytic PTLD | In plasmacytoma and plasma cell myeloma PTLD, cytogenetic abnormalities confer similar prognostic impact as in non-PTLD settings In plasmablastic lymphoma, MYC rearrangements and EBV negativity were associated with poor prognosis in one study, but not in another | Plasmacytoma-like PTLD and PCM-PTLD have survival outcomes comparable with those in the nontransplant setting14 OS in plasmablastic lymphoma ranged from 0 to 15.9 years in 1 study13 |
| PCNS-PTLD | Lack of response to high-dose MTX; older age; elevated LDH; high Ki-67 index | Median OS was 17 months in one study and 122 months in another10,11 |
| HL-PTLD | Older age; elevated creatinine; receipt of nonstandard HL therapies | 5-year OS was 57% in the largest retrospective study22 |